Nurix Therapeutics (NRIX) Non-Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Non-Current Assets data on file, last reported at $79.1 million in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 3.72% year-over-year to $79.1 million in Q2 2026; TTM through May 2026 was $324.0 million, a 37.82% increase from a year earlier, with the FY2025 full-year figure at $81.3 million, up 62.78% from the prior year.
• Non-Current Assets for Q2 2026 stood at $79.1 million, down from $81.7 million in the prior quarter.
• Over the last five years, Non-Current Assets for NRIX reached as high as $157.2 million in Q1 2022 and fell as low as $40.2 million in Q3 2023.
• Historically, Non-Current Assets has averaged $76.2 million across 5 years, with a median of $77.6 million in 2025.
• Across the five-year window, Non-Current Assets soared 83.06% in 2022 and plunged 61.47% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $98.3 million in 2022, then slumped by 38.87% to $60.1 million in 2023, then slipped by 16.87% to $50.0 million in 2024, then soared by 62.78% to $81.3 million in 2025, then retreated by 2.78% to $79.1 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $79.1 million in Q2 2026, $81.7 million in Q1 2026, and $81.3 million in Q4 2025.